

1 **Searching for prognostic biomarkers of Parkinson's Disease development in the Spanish**  
2 **EPIC cohort through a multiplatform metabolomics approach**

3 Carolina Gonzalez-Riano <sup>1</sup>, Jorge Saiz <sup>1</sup>, Coral Barbas <sup>1\*</sup>, Alberto Bergareche <sup>2,3,4\*</sup>, José M<sup>a</sup> Huerta  
4 <sup>5,6</sup>, Eva Ardanaz <sup>6,7</sup>, Marcela Konjevod <sup>8</sup>, Elisabet Mondragon <sup>2</sup>, ME Erro <sup>9</sup>, M. Dolores Chirlaque  
5 <sup>5,6</sup>, Eunat Abilleira <sup>10</sup>, Fernando Goñi-Irigoyen <sup>6,10</sup>, Pilar Amiano <sup>6,10</sup>

6

7 <sup>1</sup> Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-  
8 CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, 28660 Madrid, Spain

9 <sup>2</sup> Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain

10 <sup>3</sup> Disorders Unit, Department of Neurology, University Hospital Donostia, San Sebastián, Spain

11 <sup>4</sup> Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases  
12 (CIBERNED), Madrid, Spain

13 <sup>5</sup> Instituto Murciano de Investigación Biosanitaria (IMIB)

14 <sup>6</sup> CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

15 <sup>7</sup> Instituto de Salud Pública de Navarra, Pamplona, Spain

16 <sup>8</sup> Rudjer Boskovic Institute, Division of Molecular Medicine, Bijenicka cesta 54, 10000 Zagreb,  
17 Croatia

18 <sup>9</sup> Department of Neurology. Complejo Hospitalario de Navarra, IdiSNA (Navarra Institute for  
19 Health Research), Pamplona, Spain

20 <sup>10</sup> Public Health Laboratory in Gipuzkoa, Biodonostia Health Research Institute, San Sebastián,  
21 Spain

22

23 \* Authors to whom correspondence should be addressed:

24 e-mail address: [cbarbas@ceu.es](mailto:cbarbas@ceu.es)

25 e-mail address: JESUSALBERTO.BERGARECHEYARZA@osakidetza.eus

26

27 E-mail addresses:

28 Carolina Gonzalez-Riano: [carolina.gonzalezriano@ceu.es](mailto:carolina.gonzalezriano@ceu.es)

29 Jorge Saiz: [jorge.saizgalindo@ceu.es](mailto:jorge.saizgalindo@ceu.es)

- 30 Coral Barbas: [cbarbas@ceu.es](mailto:cbarbas@ceu.es)
- 31 Alberto Bergareche: [JESUSALBERTO.BERGARECHEYARZA@osakidetza.eus](mailto:JESUSALBERTO.BERGARECHEYARZA@osakidetza.eus)
- 32 José Mª Huerta: [jmhuerta.carm@gmail.com](mailto:jmhuerta.carm@gmail.com)
- 33 Eva Ardanaz: [mardanaa@cfnavarra.es](mailto:mardanaa@cfnavarra.es)
- 34 Marcela Konjevod: [Marcela.Konjevod@irb.hr](mailto:Marcela.Konjevod@irb.hr)
- 35 Elisabet Mondragon: [ELISABET.MONDRAGONREZOLA@osakidetza.net](mailto:ELISABET.MONDRAGONREZOLA@osakidetza.net)
- 36 ME Erro: [elena.erro.aguirre@cfnavarra.es](mailto:elena.erro.aguirre@cfnavarra.es)
- 37 M. Dolores Chirlaque: [mdolores.chirlaque@carm.es](mailto:mdolores.chirlaque@carm.es)
- 38 Eunate Abilleira: [e-abilleira@euskadi.eus](mailto:e-abilleira@euskadi.eus)
- 39 Fernando Goñi-Irigoyen: [f-goni@euskadi.eus](mailto:f-goni@euskadi.eus)
- 40 Pilar Amiano: [epics-san@euskadi.eus](mailto:epics-san@euskadi.eus)

41 **ABSTRACT**

42 **Objective:** The lack of knowledge about the onset and progression of Parkinson's disease (PD)  
43 hampers its early diagnosis and treatment. Our aim was to determine the biochemical remodeling  
44 induced by PD in a really early and pre-symptomatic stage and unveiling early potential diagnostic  
45 biomarkers adopting a multiplatform (LC-MS, GC-MS, CE-MS) untargeted metabolomics  
46 approach.

47 **Methods:** 41,437 healthy volunteers from the European Prospective Study on Nutrition and  
48 Cancer (EPIC)-Spain cohort were followed for around 15 years to ascertain incident PD. For this  
49 study, baseline pre-clinical plasma samples of 39 randomly selected individuals (46% females, 41–  
50 69 years old) that developed PD (Pre-PD group) and the corresponding control group ( $n=39$ , 46%  
51 females, 41–69 years old) were analyzed. The metabolic differences were investigated by  
52 univariate and multivariate data analyses, followed by pathway-based metabolite analyses to  
53 obtain possible clues on biological functions.

54 **Results:** Our results exposed significantly lower levels of seven free fatty acids in the pre-PD  
55 subjects, together with alterations in other metabolite classes. Our finding revealed alterations in  
56 fatty acids metabolism, mitochondrial dysfunction, oxidative stress, and gut-brain axis  
57 dysregulation.

58 **Conclusions:** Although the biological purpose of these events is still unknown, the mechanisms  
59 involved in the remodelling of the suggested metabolic pathways seem to appear long before the  
60 development of PD hallmarks. These findings might be considered as worthy potential markers  
61 whose alteration might lead to the development of PD hallmarks in the future. Consequently, this  
62 study is of inestimable value since this is the first study conducted with samples collected many  
63 years before the disease development.

64


## 65 1. INTRODUCTION

66 Parkinson's disease (PD) is a neurodegenerative disorder characterized by a loss of dopaminergic  
67 neurons in the substantia nigra and the production of Lewy bodies. Such neurological alterations  
68 cause motor and cognitive impairments<sup>1 2</sup>. Together with Alzheimer's disease, it is one of the  
69 most prevalent neurodegenerative disorders with around 2% of affected people older than 60  
70 years<sup>3 4</sup>. Diagnosis of PD is established according to the presence of parkinsonian motor  
71 symptoms, while therapy is exclusively symptomatic and cannot stop or slow down progression<sup>5</sup>.  
72 Since typical PD motor symptoms appear when there is already more than 80% of dopaminergic  
73 loss, identification of biomarkers for early diagnosis might drastically change diagnosis and  
74 treatment approaches<sup>6</sup>. Several approaches have already been proposed for the early diagnosis  
75 of PD, including positron emission tomography (PET) and single photon emission computed  
76 tomography (SPECT) imaging, examining olfactory alterations that usually appear before any  
77 known motor symptoms, skin and colonic biopsy, gene sequencing and changed metabolites,  
78 including uric acid, glutathione and  $\alpha$ -synuclein<sup>3</sup>. Since these approaches fall short for early  
79 diagnosis due to the complexity of PD, novel diagnostic approaches that would combine several  
80 methods are necessary<sup>3</sup>. Moreover, a pre-symptomatic population has never been explored  
81 searching for biomarkers.

82 In this regard, metabolomics can be considered as a well-defined approach to unveil potential  
83 metabolic biomarkers to diagnose the disease when no PD symptoms have yet developed, to  
84 understand better its early pathophysiological mechanisms, to identify potential novel drugs, and  
85 to monitor the therapeutic outcome<sup>7</sup>. Numerous original metabolomics studies have been  
86 conducted using different biological samples in order to discover potential biomarkers and  
87 altered metabolic pathways in PD. Using different analytical techniques, alterations in amino  
88 acids, dysregulation of the TCA cycle, altered fatty acid, purine, and dopamine metabolism were  
89 observed in early, mid and advanced stages of PD<sup>8 9</sup>. Recently, an LC-MS metabolomics-based

90 study conducted with plasma samples from PD patients reflected alterations in many metabolite  
91 classes, including a remarkable reduction of the levels of seventeen free fatty acids, cis-aconitic  
92 acid, and an increment on bile acids (BA) levels in PD patients<sup>10</sup>.

93 Here, we used mass spectrometry (MS) coupled to gas chromatography (GC), liquid  
94 chromatography (LC), and capillary electrophoresis (CE) to obtain a metabolome coverage as  
95 extensive as possible, aiming the analysis of the global metabolic changes in the plasma samples  
96 from participants from the European Prospective Study on Nutrition and Cancer (EPIC) that were  
97 followed for almost 15 years until June 2011. None of the participants had developed PD or  
98 showed any related symptoms at the time of sample collection. During the time they were  
99 followed up, some of them developed PD (pre-PD) while others did not (controls) (Figure 1).  
100 Consequently, these samples are of extraordinary value for discovering potential biomarkers for  
101 the early diagnosis of PD, conferring this metabolomics-based study a unique advantage in the  
102 field.



103

104 **Figure 1. Metabolomics workflow followed for this study.** Experimental design and the  
105 multiplatform untargeted metabolomics workflow followed for this study.

106

107 **2. MATERIALS AND METHODS**

108 *2.1. Patients cohort and samples*

109 The European Prospective Investigation into Cancer and Nutrition is an ongoing multicenter  
110 prospective cohort study designed to investigate the relationship between diet, nutrition and  
111 metabolic factors with cancer. Descriptions of study design, population and baseline data  
112 collection of the cohort have been reported in detail previously<sup>11</sup>. The Spanish EPIC cohort  
113 consists of 41,437 healthy participants (62% women), aged 29–69 years enrolled in 1993-1996.  
114 The EPIC-Spain Parkinson Cohort study comprises the three centres with available on Parkinson  
115 incident data Gipuzkoa, Navarra, and Murcia. The study sample consisted of 25,015 participants  
116 (57% women), aged 30–70 years at recruitment. Detailed description of lifestyle, diet,  
117 anthropometry and clinical data, case ascertainment, and the design of nested case-control study  
118 is collected in Supplementary Materials. For this multiplatform untargeted metabolomics-based  
119 study, 39 individuals that developed PD (Pre-PD group) and the corresponding control group were  
120 randomly selected, consisted both groups of 46% women, aged between 41 to 69 years old, and  
121 54% males aged between 41 to 69 years old.

122 On the day of the interview subjects were appointed for blood sample analysis within the next  
123 week at the primary care centre, where the interview took place and a 30 ml blood sample were  
124 obtained at baseline. Fasting venous blood samples were drawn and immediately processed and  
125 were divided into 0.5 ml aliquots of plasma, serum, concentrated red blood cells and buffy coat,  
126 and stored in liquid nitrogen tanks at –190°C until analysis. Quality assurance and plasma  
127 metabolites extraction was carried out according to previously reported standard protocols<sup>12-15</sup>  
128 (Supplementary Materials).

129 *2.2. Data treatment and statistical analyses*

130 LC-MS and GC-MS raw data were processed using Agilent Technologies MassHunter Profinder  
131 B.08.00 SP1 software (Waldbronn, Germany) to obtain the data matrices. For GC-MS,

132 deconvolution and identification were performed with Agilent MassHunter Unknowns Analysis  
133 Tool 9.0 using the Fiehn (v2013) and NIST (v2017) commercial libraries. The obtained GC-MS data  
134 was aligned using the MassProfiler Professional B.12.1 software (Agilent Technologies) and  
135 exported to Agilent MassHunter Quantitative Analysis version B.09.00 to assign the main ions and  
136 integrate each of the signals. Missing values were imputed using the K-nearest neighbors  
137 algorithm<sup>16</sup>. Afterward, the data matrices were filtered by coefficient of variation (CV),  
138 maintaining those signals that presented a CV < 30% in the QCs. The filtered matrices were  
139 imported into SIMCA P+15 (Umetrics, Umea, Sweden). The obtained PCA plot revealed an intra-  
140 batch effect due to gradual changes in the instrumental response that are often unavoidable,  
141 especially for long analytical sequences. In order to minimize the instrumental variation observed  
142 that hinders the power to detect the biological variation, the data were normalized by applying a  
143 correction called “quality control samples and support vector regression (QC- SVRC)”<sup>17</sup>.  
144 Furthermore, a supervised OPLS-DA model was obtained for the LC-MS ESI(+) data. The  
145 metabolites presenting a VIP  $\geq 1$  and jackknifing confidence interval not including the zero value  
146 were selected as statistically significant from the OPLS-DA model. Finally, OPLS-DA model was  
147 validated with cross-validation and CV-ANOVA tool provided by SIMPA-P+ software. The  
148 univariate data analysis was carried out using MATLAB R2015a software (Mathworks, Inc., Natick,  
149 USA), applying a t-test (p-value <0.05) and a standard Benjamini-Hochberg method was applied to  
150 control the false discovery rate (FDR) for multiple hypothesis testing. Finally, the percentage of  
151 change was calculated by comparing Pre-PD vs. control.

### 152 *2.3. LC-MS and CE-MS metabolites annotation*

153 The metabolites that turned out to be statistically significant (p-value <0.05) and showed %  
154 change greater than 20% were tentatively annotated. Initially, the m/z of the significant  
155 metabolites was searched against multiple databases available online, including METLIN  
156 (<http://metlin.scripps.edu>), LipidsMAPS (<http://lipidMAPS.org>) and KEGG

157 (<http://www.genome.jp/kegg/>), through the CEU MassMediator  
158 (<http://ceumass.eps.uspceu.es/>)<sup>18</sup>. HMDB (<http://hmdb.ca>) was also consulted for additional  
159 information. Features that were tentatively assigned to metabolites from the databases were  
160 based on: (1) mass accuracy (maximum error mass 20 ppm), (2) isotopic pattern distribution, (3)  
161 possibility of cation and anion formation, (4) adduct formation, and (5) elution order of the  
162 compounds based on the chromatographic conditions. Additionally, an 'in-house' CE-MS library  
163 built with authentic standards was used to compare the relative migration time of the significant  
164 metabolites to increase the annotations confidence. As it can be observed in Table 1, five FFAs  
165 were detected as significantly affected by two independent analytical platforms (GC-MS and LC-  
166 MS) presenting the same trend. This fact ensures the great analytical performance and  
167 reproducibility of the analyses, increases the confidence level of the metabolite annotations, and  
168 verifies the consistency of the biological results throughout the whole study.

#### 169 *2.4. Identification of potential metabolite biomarkers*

170 For biomarker prediction, the Multivariate ROC plot-based exploratory analysis (Explorer) was  
171 performed in MetaboAnalyst 4.0 (<https://www.metaboanalyst.ca/>) (Figure 2A-D). This analysis  
172 performs automated important feature identification and performance evaluation. The ROC curve  
173 analyses were based on Linear Support Vector Machine (SVM), and the ROC plots were generated  
174 by Monte-Carlo cross-validation using balanced sub-sampling. In each cross-validation, two thirds  
175 (2/3) of the samples are employed to evaluate the feature importance. The principal features are  
176 then exploited to construct the classification models, which are validated on the remaining 1/3 of  
177 the samples. The procedure is replicated multiple times to calculate the performance and the  
178 confidence interval of each model. For our data, the classification method selected was Linear  
179 SVM, and the feature ranking method selected was the SVM built-in algorithm<sup>19</sup>.

180

### 181 3. RESULTS

#### 182 3.1. Metabolite coverage by a multiplatform untargeted metabolomics-based approach

183 The metabolic fingerprint of plasma samples collected several years before the development of  
184 PD symptoms was achieved by performing a multiplatform untargeted metabolomics strategy.  
185 The metabolic alterations unveiled in this study indicate that the pathological mechanisms behind  
186 the onset and progression of PD starts many years before the appearance of the first PD  
187 symptoms. A significant amount of information was obtained from the multiplatform analysis,  
188 resulting in 672 and 571 metabolic features detected in LC-MS operated in positive and negative  
189 ionization modes, respectively, 332 signals were acquired from CE-MS and 104 from GC-MS  
190 analysis. After raw data matrix normalization, curation, and statistical analysis, 15, 12, 9, and 3  
191 metabolites were detected as significantly affected by LC-MS-ESI(-), LC-MS-ESI(+), GC-MS, and CE-  
192 MS, respectively (Table 1).

193 To enrich the biological interpretation of the results, we will discuss about the important changes  
194 displayed by cis-aconitic acid, 2'-deoxyuridine-5'-monophosphate (dUMP), and serotonin  
195 although they were not statistically significant. After data normalization, all the PCA plots  
196 obtained displayed a tightly clustering of the QC samples, revealing the correction of the  
197 instrumental variation (Figure S1). Surprisingly, a supervised OPLS-DA model was obtained for the  
198 LC-MS-ESI(+) data with great quality parameters values ( $R^2 = 0.996$ ,  $Q^2 = 0.687$ )<sup>20</sup>. Finally, the  
199 models were validated by cross-validation and CV-ANOVA tool provided by SIMCA-P+ software ( $p$   
200 CV-ANOVA= $1.31 \times 10^{-8}$ ) (Figure S2).

#### 201 3.2. Metabolic alterations detected in plasma samples of pre-PD subjects

202 Most of the identified signals in LC-MS-ESI(+) were glycerophospholipids, while in LC-MS-ESI(-)  
203 most common metabolites were saturated (SFA), monounsaturated (MFA), and polyunsaturated  
204 (PUFA) fatty acids. The levels of four LPC species were increased, while PC(36:5) and PC(28:2)  
205 were significantly decreased in pre-PD group. Additionally, the BA levels were upregulated in pre-  
206 PD samples (Figure 3). However, the type of BA was not established according to the spectra and

207 it was only identified according to the compound group. The Palmitoleoyl ethanolamide,  
208 MG(18:2), 3-ketosphingosine, and vitamin D2/5-dehydroepisterol were also increased in Pre-PD  
209 plasma samples. Regarding the LC-MS-ESI(-), the DPA, arachidonic, linoleic, oleic, stearic, palmitic,  
210 and palmitoleic acids were decreased in plasma samples of pre-PD subjects compared with  
211 controls, same as levels of tetrahydroaldosterone-3-glucuronide and CMPF. As in LC-MS-ESI(-),  
212 most of the significantly affected compounds obtained by GC-MS were also FFAs. Palmitoleic,  
213 linoleic, oleic, palmitic, and stearic acids were significantly decreased in Pre-PD plasma samples  
214 (Table 1) (Figure 3). Furthermore,  $\beta$ -hydroxybutyric acid, 2-hydroxy-3-methylbutyric acid,  
215 lactamide, and threitol levels were reduced in pre-PD subjects. Regarding CE-MS, the  
216 pipercolic acid and 2-aminobenzoic acid levels were decreased, while the 3-methoxytyrosin  
217 showed an increment in the plasma samples of pre-PD group. Finally, the potential biomarkers  
218 obtained from the multivariate ROC curve exploration module, oleic acid, LPC(22:6), linoleic acid,  
219 pipercolic acid, PC(36:5), CMPF, palmitic acid, vitamin D3 metabolite, arachidonic acid, 3-  
220 ketosphingosine, BA, 2-aminobenzoic acid, palmitoleic acid, lactamide, MG(18:2), and dUMP,  
221 presented a selection frequency between 0.8 and 1.0 (*i.e.* selected between 80% to 100% of the  
222 time in the model) of the SVM feature selection algorithm (Figure 2D).

223

224 **Table 1.** Metabolites that showed statistical significance when comparing PD subjects and healthy  
 225 controls.


Metabolite	Mass	<sup>a</sup> RT (min)	<sup>b</sup> RMT	Technique	Error (ppm)	Adduct	<sup>c</sup> CV (% in QC)	<sup>d</sup> % change	<sup>e</sup> p value	<sup>f</sup> VIP
<i>Benzene and substituted derivatives</i>										
2-Aminobenzoic acid	137.0476	15.47	0.90	CE-MS	8	[M+H] <sup>+</sup>	2.7	-40.1	0.012	-
<i>Carboxylic acids and derivatives</i>										
Cis-aconitic acid	174.0164	15.72	-	GC-MS	-	-	12.5	-23.1	0.056	-
3-Methoxytyrosine	211.0844	29.85	1.73	CE-MS	1	[M+H] <sup>+</sup>	4.3	16.0	0.026	-
Pipecolic acid	129.0789	15.15	0.88	CE-MS	6	[M+H] <sup>+</sup>	4.3	-52.1	0.024	-
<i>Fatty acyls</i>										
2-Hydroxy-3-methylbutyric acid	118.0629	8.30	-	GC-MS	-	-	4.5	-29.5	0.037	-
CMPP	240.0998	7.08	-	LC-MS ESI (±)	1	[M-H] <sup>-</sup>	3.6	31.7	0.035	-
Arachidonic acid	304.2402	31.02	-	LC-MS ESI (-)	8	[M+FA-H] <sup>-</sup>	4.1	-16.1	0.049	-
Docosapentaenoic acid (DPA)	330.2555	28.29	-	LC-MS ESI (-)	1	[M-H] <sup>-</sup>	4.2	-20.3	0.041	-
Linoleic acid	280.2402	20.38	-	GC-MS / LC-MS ESI (-)	-	-	5.4	-29.5	0.035	-
Oleic acid	282.2558	20.40	-	GC-MS / LC-MS ESI (-)	-	-	5.5	-28.9	0.039	-
Palmitic acid	256.2402	18.85	-	GC-MS / LC-MS ESI (-)	-	-	4.6	-20.7	0.016	-
Palmitoleic acid	254.2245	18.67	-	GC-MS / LC-MS ESI (-)	-	-	5.3	-33.9	0.017	-
Palmitoleoyl-EA	297.2667	21.15	-	LC-MS ESI (+)	1	[M+H] <sup>+</sup>	10.3	29.7	0.10	1.1
Stearic acid	284.2715	20.68	-	GC-MS/ LC-MS ESI (-)	-	-	10.3	-17.4	0.0056	-
<i>Glycerolipids</i>										
MG(18:2)	354.2770	25.65	-	LC-MS ESI (+)	7	[M+H] <sup>+</sup>	23.3	36.1	0.024	1.4
<i>Glycerophospholipids</i>										
LPC(16:1)	493.3168	17.38	-	LC-MS ESI (+)	1	[M+H] <sup>+</sup>	9.3	21.1	0.054	1.2
LPC(17:1)	507.3316	18.22	-	LC-MS ESI (+)	2	[M+H] <sup>+</sup>	6.4	16.4	0.086	1.2
LPC(P-18:0)	507.3689	21.05	-	LC-MS ESI (+)	1	[M+H] <sup>+</sup>	4.2	14.6	0.10	1.2
LPC(22:6)	613.3371	17.71	-	LC-MS ESI (-)	1	[M+FA-H] <sup>-</sup>	4.1	15.8	0.049	-
PC(28:2)	709.4338	31.03	-	LC-MS ESI (-)	16	[M+Cl] <sup>-</sup>	6.6	-32.5	0.033	-
PC(36:5)	779.5465	31.18	-	LC-MS ESI (+)	1	[M+H] <sup>+</sup>	23.8	-31.2	0.014	1.2
<i>Hydroxy acids and derivatives</i>										
β-Hydroxybutyric acid	104.0473	8.25	-	GC-MS	-	-	5.3	-51.3	0.0079	-
<i>Indoles and derivatives</i>										
Serotonin	176.0949	13.21	0.76	CE-MS	2	[M+H] <sup>+</sup>	5.9	-43.9	0.15	-
<i>Monocarboxylic acid amide</i>										
Lactamide	89.0477	8.24	-	GC-MS	-	-	5.5	-29.1	0.0079	-
<i>Organoxygen compounds</i>										
Threitol	122.0579	12.89	-	GC-MS	-	-	5.4	-17.2	0.040	-
<i>Pyrimidine nucleotides</i>										
dUMP	308.0409	29.84	1.73	CE-MS	7	[M+H] <sup>+</sup>	12.7	31.6	0.051	-
<i>Sphingolipids</i>										
3-ketosphingosine	297.2667	20.61	-	LC-MS ESI (+)	1	[M+H] <sup>+</sup>	17.5	35.2	0.063	1.2
PE-Cer(d30:2)	602.4423	30.54	-	LC-MS ESI (-)	10	[M-H] <sup>-</sup>	7.2	-22.7	0.042	-
<i>Steroids and steroid derivatives</i>										
Tetrahydroaldosterone-3-glucuronide	540.2570	1.08	-	LC-MS ESI (-)	3	[M-H] <sup>-</sup>	5.1	20.3	0.042	-
<i>Multiple candidates</i>										
Bile acid 1	374.2825	14.78	-	LC-MS ESI (+)	1	[M+H-H <sub>2</sub> O] <sup>+</sup>	9.7	57.6	0.032	1.3
Bile acid 2	396.2884	22.36	-	LC-MS ESI (+)	2	[M-H] <sup>-</sup>	11.6	219.1	0.041	1.0
Vitamine D2 / 5-Dehydroepisterol	379.3289	23.95	-	LC-MS ESI (+)	18	[M+H-H <sub>2</sub> O] <sup>+</sup>	5	15.4	1.62x10 <sup>-7</sup>	2.7
Vitamine D3 metabolite	446.3387	30.48	-	LC-MS ESI (-)	1	[M-H] <sup>-</sup>	14.4	52.2	0.0063	-
<i>Unknowns</i>										
Unknown 1	445.1517	27.06	-	LC-MS ESI (-)	-	-	4.7	-26.3	0.026	-
Unknown 2	554.2056	31.03	-	LC-MS ESI (-)	-	-	8.3	-25.6	0.047	-
Unknown 3	563.4327	31.27	-	LC-MS ESI (+)	-	-	10.7	27.1	0.037	1.4

226 <sup>a</sup>RT: retention time expressed in minutes; <sup>b</sup>Relative MT (RMT): RMT based on the MT of the IS added to each sample;

227 <sup>c</sup>CV: coefficient of variation calculated in the QCs (30%); <sup>d</sup>% change: calculated between pre-PD and controls, the sign (-)


228 indicates that this metabolite is less abundant in pre-PD subjects than in controls; <sup>e</sup> corrected p-value obtained with the

229 t-test; <sup>f</sup>VIP: Variable of Importance in Projection.



230

231 **Figure 2. Biomarker prediction by Multivariate ROC curve based exploratory analysis. A**  
 232 **Overview of all ROC curves created by MetaboAnalyst 4.0 from 6 different biomarker models**  
 233 **considering different number of features (2, 3, 5, 10, 20, and 33) with their corresponding AUC**  
 234 **value and confidence interval; B Predictive accuracies of 6 different biomarker models. The red**  
 235 **dot specifies the highest accuracy for the 20-feature panel of model 5; C ROC curve for selected**  
 236 **biomarker model 5; D Top 28 potential biomarkers predicted based on their frequencies of being**  
 237 **selected during cross validation.**



238

239 **Figure 3. Abundance of the statistically significant FFAs, BA, pipecolic acid, and β-**  
 240 **hydroxybutyric acid.** The graphic reflects the differences between the pre-PD (grey bar) and the  
 241 control (blue bar) group. The error bars represent the standard error of the mean (SEM). \*p ≤  
 242 0.05; \*\*p ≤ 0.001.

243 **4. DISCUSSION**


244 Parkinson's disease is a progressive, complex, multisystem neurodegenerative disorder,  
 245 characterized by typical movement symptoms<sup>21</sup> and cognitive impairments that affect usual  
 246 functioning. Due to complexity and heterogeneity, several metabolic pathways are involved in its  
 247 development and pathogenesis<sup>9</sup>. It is crucial to enlighten that metabolites mentioned below were  
 248 already altered before PD development because the sampling was performed while subjects still  
 249 did not have any symptoms.

250

251

252 4.1.1. Fatty acid metabolism alterations

253 In this study, decreased levels of multiple fatty acyls including SFA, MUFA, and PUFA were noticed  
254 in pre-symptomatic PD subjects (Figure 4). This is in agreement with recent studies that  
255 recognized a remarkable reduction of the levels of several FFAs in PD patients<sup>8 10 22</sup>.



256

257 **Figure 4. FFAs metabolism and their trends observed in this study when compared the pre-PD**  
258 **group with control subjects.** The arrows represent the trend of each metabolite within the  
259 comparison, displaying their corresponding percentages of change.

260 Fatty acids are vital for a correct brain function since it depends on dietary fatty acid intake. Lipids  
261 and fatty acid dyshomeostasis is associated with many neurodegenerative disorders,  
262 neuroinflammation and oxidative stress<sup>23</sup>, same as with apoptotic signaling and mitochondrial  
263 dysfunction<sup>8 9</sup>. Currently, it seems that there is not direct connection between the SFA intake and  
264 PD risk in humans<sup>24</sup>. Higher palmitic and stearic acids levels have been observed in lipid rafts from  
265 the frontal cortex of PD patients compared to healthy controls<sup>25</sup>. Moreover, the alpha-synuclein  
266 modulates the uptake of palmitic acid into the brain<sup>26</sup>. Therefore, the accumulation of this protein  
267 in PD brains might lead to increased levels of palmitic acid, which in turn can trigger some of its  
268 neuropathological activities. Consequently, it can be hypothesized that the lower levels of both

269 SFA in plasma of the pre-PD subjects might be due to an early and progressive migration and  
270 reuptake of these fatty acids to the brain. Regarding the MUFA, palmitoleic and oleic acids are  
271 recognized of great importance for human metabolism since they are considered anti-  
272 inflammatory compounds with neuronal protective effects<sup>27</sup>. Palmitoleic acid is one of the  
273 principal components of the human adipose tissue, muscle, and liver together with palmitic,  
274 stearic, oleic, and linoleic acids, whose levels have been also detected as significantly reduced in  
275 the PD group. A recent study has demonstrated that oleic acid presents detrimental effects in the  
276  $\alpha$ -synuclein homeostasis since it induces  $\alpha$ -synuclein inclusion formation in human neural cells<sup>28</sup>.  
277 Therefore, the lower levels of oleic acid in plasma might be also due to its early reuptake by the  
278 brain. Regarding the PUFAs, although the epidemiological evidence suggesting that dietary fat  
279 consumption may be associated with PD risk is not consistent, a significant number of PD animal  
280 models and epidemiological research studies have proved that PUFAs might play many critical  
281 roles in this regard<sup>29</sup>. The elevated PD risk may result from the dietary fat effects, including  
282 increased oxidative stress and neuroinflammation, which can potentially worsen the  
283 dopaminergic neuron loss due to neurotoxicity<sup>29</sup>.

284 Although increased levels of SFAs has been observed in a 6-OHDA rat model of PD<sup>30</sup>, a recent  
285 study conducted with plasma samples collected from PD patients' uncovered diminished levels of  
286 4 SFAs, including the stearic acid in the PD group compared with their corresponding control  
287 group<sup>10</sup>. The study also revealed reduced levels of 4 MFA, including the oleic acid, and 9 PUFA,  
288 including the linoleic acid, arachidonic acid, and DPA<sup>10</sup>.

#### 289 *4.1.2. Pipecolic acid and the gut-brain axis*

290 It is becoming increasingly evident that intestinal microbiota influences gut-brain axis  
291 communication. Indeed, the premise that PD development is triggered following continuous gut  
292 aggravation has gathered significant strength recently<sup>31</sup>. In fact, the enteric  $\alpha$ Syn has been  
293 associated with greater intestinal permeability<sup>32</sup>. It exists a positive relationship between

294 inflammatory bowel diseases and future PD risk in various populations<sup>33</sup>. A previous study  
295 demonstrated how metabolites involved in the correct brain function were influenced by the  
296 intestinal microbiota, including the pipercolic acid<sup>34</sup>. This metabolite comes from the degradation  
297 of lysine in the cerebral peroxisomes. These multifunctional organelles are involved in ROS  
298 metabolism, fatty acid oxidation, ether lipid synthesis, BA synthesis, and cholesterol transport.  
299 Peroxisomal dysfunction has been linked to neurodegenerative disorders, including Parkinson's  
300 disease (PD)<sup>35</sup>. Pipercolic acid can act also as neurotransmitter modulating the gamma-  
301 aminobutyric acid (GABA)ergic transmission<sup>36</sup>. It can be taken up by cerebral mitochondria, the  
302 principal responsible of cellular apoptosis activation, stimulating the neuronal cell death<sup>36</sup>.  
303 Therefore, decreased levels of pipercolic acid might be indicative of the initial stages of the gut-  
304 brain axis dysregulation and a peroxisomal failure. Additionally to pipercolic acid, we did not  
305 observe any other significantly changed amino acid, while other articles reported alterations on  
306 their levels in PD subjects<sup>8,9</sup>. As our study samples were collected prior to disease development,  
307 changes in these compounds might be considered as metabolic biomarkers of advanced stages of  
308 the PD.

#### 309 *4.1.3. Ketone bodies and mitochondrial function impairment*

310 We found decreased  $\beta$ -Hydroxybutyric acid levels in Pre-PD cohort. This ketone body is  
311 synthesized in liver mitochondria from acetyl-CoA and serves as an alternative fuel source for  
312 extrahepatic tissues including the brain. It is a product of healthy metabolism of fatty acid  
313 oxidation together with acetoacetate. It has been described that  $\beta$ -Hydroxybutyric acid  
314 administration protects both mesencephalic and dopaminergic neurons from MPP<sup>+</sup> and MPTP  
315 toxicity, respectively<sup>37</sup>. Moreover, patients able to tolerate a ketogenic diet improved their  
316 Unified Parkinson Disease Rating Scale scores with no harmful effects<sup>38</sup>. Consequently, a decrease  
317 in this metabolites levels might indicate the initial stage of the mitochondrial impairment that  
318 plays a central role in the PD pathophysiology.



320                   4.1.4. *Energy production alterations*

321   Increased levels of BA have also been observed. In accordance with our results, it has been  
322   recently described an increment of BA levels in plasma samples of PD patients<sup>10</sup>. Consequently,  
323   elevations of BA levels can also be detected many years before the PD development. Due to their  
324   role, it is assumed that down-regulation of fatty acids and phospholipids and other perturbations  
325   in lipid metabolism might be associated with impaired BA metabolism. Consequently, it could  
326   cause further disturbances in energy production in PD subjects<sup>39</sup>. Together with fatty acid  
327   metabolism, TCA cycle plays an important role in energy metabolism. Dysregulation of TCA cycle  
328   is possibly associated with PD progression and  $\alpha$ -synuclein pathology, while fatty acid metabolism  
329   might be associated with  $\alpha$ -synuclein aggregation<sup>9</sup>. We identified decreased levels of cis-aconitic  
330   acid in Pre-PD subjects. It is assumed that TCA cycle has an important role as part of energy  
331   metabolism in degeneration of dopaminergic cells through complex *gene x environment*  
332   interaction<sup>9</sup>. At the beginning of neurodegenerative processes in PD, TCA cycle is downregulated  
333   due to mitochondrial dysfunction or energy deficient<sup>9</sup>, which is in correspondence with  
334   downregulation of fatty acid metabolites also due to disturbances in mitochondrial function and  
335   energy production<sup>39</sup>. Although the difference between pre-PD subjects and controls was not  
336   significant in our study, it has been newly uncovered diminished cis-aconitic acid levels in PD  
337   patients<sup>10</sup>. Therefore, reduced levels of TCA cycle metabolites might be related to the future  
338   onset of PD.

339                   4.1.5. *Tryptophan metabolism and PD onset*

340   The metabolism of tryptophan is associated with PD progression and development<sup>9</sup>. Postmortem  
341   examinations in PD patients showed decreased levels of metabolites involved in tryptophan  
342   pathway, same as altered tryptophan levels in CSF and plasma. It is assumed that dysregulation of  
343   this metabolism leads to neurotoxicity<sup>40</sup>, which might act as a trigger for PD development. This  
344   study has shown decreased levels of tryptophan co-metabolites, such as 2-aminobenzoic acid and  
345   serotonin in PD patients. Unlike serotonin, 2-aminobenzoic acid was significantly decreased in PD

346 subjects, which might confirm possible association of altered tryptophan metabolism in early  
347 stage of disease development.

## 348 **5. CONCLUSIONS**

349 Through a multiplatform untargeted metabolomics-based approach we have identified, for the  
350 first time, 33 altered metabolites in plasma samples from subjects that did not present any  
351 pathology when the samples were collected and, many years later, they developed PD. Several  
352 pieces of evidence indicate the implication of mitochondrial dysfunction and oxidative stress,  
353 which is reflected in the metabolite changes of PD pathogenesis. According to our data, it is  
354 evident that changes in fatty acid metabolism and their corresponding metabolic pathways are  
355 altered long before PD's first symptoms are observed. Likewise, in our study, these metabolites  
356 levels were significantly reduced compared to subjects that did not develop PD during the time  
357 they were followed up. Our results are mostly in agreement with recent metabolomics-based  
358 findings where decreased levels of 17 FFAs and cis-aconitic acid and increased BA levels were  
359 found in plasma samples collected from PD patients. This fact indicates that these metabolite  
360 modifications begin many years before the PD development and are maintained when suffering  
361 this disease. Furthermore, the detected alteration in pipercolic acid levels leads to hypothesize  
362 about the early triggering of the gut-brain axis dysregulation and peroxisomal failure. Although  
363 the biological purpose of these events is still unknown, the mechanisms involved in the suggested  
364 mitochondrial dysfunction, oxidative stress, and gut-brain axis dysregulation seem to appear long  
365 before the development of this disease. Therefore, the remodeled metabolic pathways  
366 highlighted in this study might be considered as worthy potential markers whose alteration might  
367 lead to the development of PD hallmarks in the future.

368 *Abbreviations:* BA, bile acids; CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid, DPA,  
369 docosapentaenoic acid; EPIC, European Prospective Study on Nutrition and Cancer; FFAs, free  
370 fatty acids; LPC, lysoglycerophosphocholines; MFA, monounsaturated fatty acid; MPP<sup>+</sup>, 1-Methyl-

371 4-phenylpyridinium; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PC,  
372 glycerophosphocholines; pre-PD, pre-Parkinson's Disease development group; PUFA,  
373 polyunsaturated fatty acid; QC-SVRC, quality control samples and support vector regression; RMT,  
374 relative migration time; SFA, saturated fatty acid; SVM, Support Vector Machine.

## 375 **DECLARATIONS**

### 376 **Ethics approval and consent to participate**

377 This study was approved by the Ethics Committee for clinical research of the Basque Country  
378 PI2017031.

### 379 **Availability of data and materials**

380 The datasets used and/or analyzed during the current study are available from the corresponding  
381 author on reasonable request.

### 382 **Competing interests**

383 The authors have declared that no competing interests exist.

### 384 **Funding sources**

385 This study was supported by grants from the following entities: Basque Government, Spain  
386 (GV2016111098), the Spanish Ministry of Science, Innovation and Universities (grant RTI2018-  
387 095166-B-I00 to C.B.), and FEDER Program 2014-2020 of the Community of Madrid  
388 (S2017/BMD3684).

### 389 **Authors' Contributions**

390 AB, PA, JMH, EA, FGI, CB were involved in study concept and design. JS, MK, CGR, CB, JMH, EA,  
391 PA, AB, MDC were involved in data acquisition. CGR and CB were involved in data analysis. CGR,  
392 JS, CB, AB, PA, JMH, EA, FGI, EA were involved in data interpretation. CB, AB, FGI, PA were  
393 involved in the work supervision. CGR, JS, MK, CB were involved in drafting the manuscript. CGR,

394 CB, MEE, EM, AB, PA, JMH, EA, FGI, EA, MDC were involved in critical revision of the manuscript  
395 for important intellectual content. All authors read and approved the final manuscript.

396 **SUPPLEMENTARY MATERIALS**

397 **Additional file**

- 398 - Study population details – page 4
- 399 - Chemicals, metabolites extraction protocols, and quality assurance – pages 7-8
- 400 - Run settings and data acquisition for LC-MS, GC-MS, and CE-MS – page 9
- 401 - Strengths and limitations of the study – page 12
- 402 - Figure S1. PCA-X score plot for the 3 analytical platforms – page 13
- 403 - Figure S2. Supervised OPLS-DA plot of LC-MS (+) data analysis – page 13

404     **REFERENCES**

- 405     1. Han W, Sapkota S, Camicioli R, et al. Profiling novel metabolic biomarkers for Parkinson's  
406             disease using in-depth metabolomic analysis. *Movement Disorders* 2017;32(12):1720-28.
- 407     2. Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. *Journal of neurochemistry*  
408             2016;139:318-24.
- 409     3. De Virgilio A, Greco A, Fabbrini G, et al. Parkinson's disease: autoimmunity and  
410             neuroinflammation. *Autoimmunity reviews* 2016;15(10):1005-11.
- 411     4. Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. *Journal of neurochemistry*  
412             2016;139:216-31.
- 413     5. Cookson MR. Chapter 6 - Parkinson's disease. In: Baekelandt V, Lobbstaël E, eds. Disease-  
414             Modifying Targets in Neurodegenerative Disorders: Academic Press 2017:157-74.
- 415     6. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology  
416             of axons. *Annals of neurology* 2010;67(6):715-25.
- 417     7. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine.  
418             *Nature Reviews Drug Discovery* 2016;15(7):473-84. doi: 10.1038/nrd.2016.32
- 419     8. Havelund JF, Heegaard NH, Færgeman NJ, et al. Biomarker research in Parkinson's disease  
420             using metabolite profiling. *Metabolites* 2017;7(3):42.
- 421     9. Shao Y, Le W. Recent advances and perspectives of metabolomics-based investigations in  
422             Parkinson's disease. *Molecular neurodegeneration* 2019;14(1):3.
- 423     10. Shao Y, Li T, Liu Z, et al. Comprehensive metabolic profiling of Parkinson's disease by liquid  
424             chromatography-mass spectrometry. *Molecular neurodegeneration* 2021;16(1):1-15.
- 425     11. Riboli E, Hunt K, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition  
426             (EPIC): study populations and data collection. *Public health nutrition* 2002;5(6b):1113-24.
- 427     12. Naz S, Calderón ÁA, García A, et al. Unveiling differences between patients with acute  
428             coronary syndrome with and without ST elevation through fingerprinting with CE-MS and  
429             HILIC-MS targeted analysis. *Electrophoresis* 2015;36(18):2303-13.
- 430     13. Garcia A, Barbas C. Gas chromatography-mass spectrometry (GC-MS)-based metabolomics.  
431             *Metabolic Profiling*: Springer 2011:191-204.
- 432     14. Ciborowski M, Javier Ruperez F, Martínez-Alcázar MP, et al. Metabolomic approach with LC-  
433             MS reveals significant effect of pressure on diver's plasma. *Journal of Proteome Research*  
434             2010;9(8):4131-37.
- 435     15. Dudzik D, Barbas-Bernardos C, García A, et al. Quality assurance procedures for mass  
436             spectrometry untargeted metabolomics. a review. *Journal of pharmaceutical and*  
437             *biomedical analysis* 2017

- 438 16. Armitage EG, Godzien J, Alonso-Herranz V, et al. Missing value imputation strategies for  
439 metabolomics data. *Electrophoresis* 2015;36(24):3050-60.
- 440 17. Kuligowski J, Sánchez-Illana Á, Sanjuán-Herráez D, et al. Intra-batch effect correction in liquid  
441 chromatography-mass spectrometry using quality control samples and support vector  
442 regression (QC-SVRC). *Analyst* 2015;140(22):7810-17.
- 443 18. Gil-De-La-Fuente A, Godzien J, Saugar S, et al. CEU Mass Mediator 3.0: A Metabolite  
444 Annotation Tool. *Journal of Proteome Research* 2019;18(2):797-802.
- 445 19. Barberini L, Noto A, Saba L, et al. Multivariate data validation for investigating primary HCMV  
446 infection in pregnancy. *Data in brief* 2016;9:220-30.
- 447 20. Godzien J, Ciborowski M, Angulo S, et al. From numbers to a biological sense: How the  
448 strategy chosen for metabolomics data treatment may affect final results. A practical  
449 example based on urine fingerprints obtained by LC-MS. *Electrophoresis*  
450 2013;34(19):2812-26. doi: 10.1002/elps.201300053
- 451 21. Emamzadeh FN, Surguchov A. Parkinson's disease: biomarkers, treatment, and risk factors.  
452 *Frontiers in neuroscience* 2018;12:612.
- 453 22. Schmid SP, Schleicher ED, Cegan A, et al. Cerebrospinal fluid fatty acids in  
454 glucocerebrosidase-associated Parkinson's disease. *Movement disorders* 2012;27(2):288-  
455 93.
- 456 23. Willkommen D, Lucio M, Moritz F, et al. Metabolomic investigations in cerebrospinal fluid of  
457 Parkinson's disease. *PloS one* 2018;13(12)
- 458 24. Miyake Y, Sasaki S, Tanaka K, et al. Dietary fat intake and risk of Parkinson's disease: a case-  
459 control study in Japan. *Journal of the neurological sciences* 2010;288(1-2):117-22.
- 460 25. Fabelo N, Martín V, Santpere Baró G, et al. Severe alterations in lipid composition of frontal  
461 cortex lipid rafts from parkinson's disease and incidental parkinson's. *Molecular Medicine*,  
462 2010, vol 17, num 9-10, p 1107-1118 2010
- 463 26. Golovko MY, Faergeman NJ, Cole NB, et al.  $\alpha$ -synuclein gene deletion decreases brain  
464 palmitate uptake and alters the palmitate metabolism in the absence of  $\alpha$ -synuclein  
465 palmitate binding. *Biochemistry* 2005;44(23):8251-59.
- 466 27. Frigolet ME, Gutiérrez-Aguilar R. The role of the novel lipokine palmitoleic acid in health and  
467 disease. *Advances in Nutrition* 2017;8(1):173S-81S.
- 468 28. Fanning S, Haque A, Imberdis T, et al. Lipidomic analysis of  $\alpha$ -synuclein neurotoxicity identifies  
469 stearoyl CoA desaturase as a target for Parkinson treatment. *Molecular cell*  
470 2019;73(5):1001-14. e8.
- 471 29. Qu Y, Chen X, Xu M-M, et al. Relationship between high dietary fat intake and Parkinson's  
472 disease risk: a meta-analysis. *Neural regeneration research* 2019;14(12):2156.

473 30. Shah A, Han P, Wong M-Y, et al. Palmitate and Stearate are Increased in the Plasma in a 6-  
474 OHDA Model of Parkinson's Disease. *Metabolites* 2019;9(2):31.

475 31. Foster JA, Neufeld K-AM. Gut-brain axis: how the microbiome influences anxiety and  
476 depression. *Trends in neurosciences* 2013;36(5):305-12.

477 32. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with  
478 sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early  
479 Parkinson's disease. *PloS one* 2011;6(12)

480 33. Gorecki AM, Preskey L, Bakeberg MC, et al. Altered gut microbiome in Parkinson's disease and  
481 the influence of lipopolysaccharide in a human  $\alpha$ -synuclein over-expressing mouse model.  
482 *Frontiers in neuroscience* 2019;13:839.

483 34. Matsumoto M, Kibe R, Ooga T, et al. Cerebral low-molecular metabolites influenced by  
484 intestinal microbiota: a pilot study. *Frontiers in systems neuroscience* 2013;7:9.

485 35. Cipolla CM, Lodhi IJ. Peroxisomal dysfunction in age-related diseases. *Trends in Endocrinology*  
486 *& Metabolism* 2017;28(4):297-308.

487 36. Matsumoto S, Yamamoto S, Sai K, et al. Pipecolic acid induces apoptosis in neuronal cells.  
488 *Brain research* 2003;980(2):179-84.

489 37. Tieu K, Perier C, Caspersen C, et al. D- $\beta$ -Hydroxybutyrate rescues mitochondrial respiration  
490 and mitigates features of Parkinson disease. *The Journal of clinical investigation*  
491 2003;112(6):892-901.




492 38. VanItallie TB, Nonas C, Di Rocco A, et al. Treatment of Parkinson disease with diet-induced  
493 hyperketonemia: a feasibility study. *Neurology* 2005;64(4):728-30.

494 39. Zhao H, Wang C, Zhao N, et al. Potential biomarkers of Parkinson's disease revealed by plasma  
495 metabolic profiling. *Journal of Chromatography B* 2018;1081:101-08.

496 40. Szabó N, Kincses ZT, Toldi J, et al. Altered tryptophan metabolism in Parkinson's disease: a  
497 possible novel therapeutic approach. *Journal of the neurological sciences* 2011;310(1-  
498 2):256-60.

499



**A****B****C****D**